Scarica l'app Stockscreener
2.395
2.05%
-0.045
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$2.44
Aprire:
$2.46
Volume 24 ore:
4.44M
Relative Volume:
0.49
Capitalizzazione di mercato:
$2.26B
Reddito:
$1.31M
Utile/perdita netta:
$-597.65M
Rapporto P/E:
-2.4691
EPS:
-0.97
Flusso di cassa netto:
$-425.62M
1 W Prestazione:
-5.91%
1M Prestazione:
-7.00%
6M Prestazione:
-2.85%
1 anno Prestazione:
-26.01%
Intervallo 1D:
$2.38
$2.48
Intervallo di 1 settimana:
$2.38
$2.61
Portata 52W:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Confronta IBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.395 | 2.31B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.44 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.71 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.08 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.28 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
322.77 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Immunitybio Inc Borsa (IBRX) Ultime notizie
Will ImmunityBio Inc. rebound enough to break evenShort Setup & Weekly Market Pulse Updates - newser.com
Why ImmunityBio Inc. (26CA) stock is a strong analyst pickDollar Strength & Fast Entry High Yield Stock Tips - newser.com
Will EnGene Join The Ranks Of Merck, Ferring, And ImmunityBio In Bladder Cancer Treatment? - RTTNews
Will ImmunityBio Inc. stock outperform tech sector in 2025Quarterly Performance Summary & Precise Swing Trade Alerts - newser.com
How ImmunityBio Inc. stock reacts to job market data2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
Real time social sentiment graph for ImmunityBio Inc.2025 Pullback Review & Accurate Intraday Trading Signals - newser.com
Evaluating ImmunityBio Inc. with trendline analysis2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
Is ImmunityBio Inc. (26CA) stock prepared for digital transitionJuly 2025 Technicals & Smart Allocation Stock Tips - newser.com
ImmunityBio Inc. stock retracement – recovery analysis2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
Will ImmunityBio Inc. stock benefit from infrastructure spendingJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
ANKTIVA Reimbursement Gains and UK Approval Might Change The Case For Investing In ImmunityBio (IBRX) - Sahm
What Went Wrong With ImmunityBio’s Executives Claims — and How Investors Could Still Win - TradingView
ImmunityBio: A Small Bet Is Warranted (NASDAQ:IBRX) - Seeking Alpha
NMIBC Market to Experience Notable Growth in Forecast Span - openPR.com
Short interest data insights for ImmunityBio Inc.Earnings Growth Report & Technical Pattern Recognition Alerts - newser.com
Does ImmunityBio Inc. show high probability of reboundJuly 2025 Pullbacks & Stepwise Trade Signal Implementation - newser.com
What MACD and RSI say about ImmunityBio Inc.July 2025 Retail & Weekly High Return Stock Opportunities - newser.com
ImmunityBio (IBRX): Revisiting Valuation After ANKTIVA’s Regulatory Wins and New Growth Initiatives - Sahm
How high can ImmunityBio Inc. stock go2025 Volume Leaders & AI Powered Trade Plan Recommendations - newser.com
Wall Street Bullish on ImmunityBio (IBRX) Since the Announcement of New Findings From QUILT-3.055 Study - MSN
ImmunityBio’s (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients - MSN
ImmunityBio, Inc. (IBRX) Reports Strong Q2 Growth, Eyes Lung Cancer and NMIBC Expansion - Insider Monkey
What drives ImmunityBio Inc stock priceStock Liquidity Analysis & Free Trend Following Techniques - earlytimes.in
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunitybio Inc Azioni (IBRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '25 |
Option Exercise |
0.00 |
114,329 |
0 |
29,588,261 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '25 |
Option Exercise |
0.00 |
40,650 |
0 |
241,480 |
| Adcock Richard | CEO & President |
Feb 22 '25 |
Option Exercise |
0.00 |
152,439 |
0 |
412,585 |
| Simon Barry J. | Director |
Feb 22 '25 |
Option Exercise |
0.00 |
15,243 |
0 |
3,249,024 |
| Simon Barry J. | Director |
Jan 22 '25 |
Option Exercise |
2.00 |
110,020 |
219,864 |
3,233,781 |
| Adcock Richard | CEO & President |
Dec 31 '24 |
Option Exercise |
0.00 |
34,483 |
0 |
277,621 |
| Sachs David C. | Chief Financial Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
30,397 |
0 |
216,235 |
| LAUER REGAN J | Chief Accounting Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
21,031 |
0 |
115,365 |
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):